Page 1473 - Hematology_ Basic Principles and Practice ( PDFDrive )

1308.e2 Part VII Hematologic Malignancies

lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes 50. Goy A, Bernstein SH, Kahl BS, et al: Bortezomib in patients with
de l’Adulte. Blood 121(1):48–53, 2013. relapsed or refractory mantle cell lymphoma: updated time-to-event
34. Martin P, Chadburn A, Christos P, et al: Outcome of deferred initial analyses of the multicenter phase 2 PINNACLE study. Ann Oncol
therapy in mantle-cell lymphoma. J Clin Oncol 27(8):1209–1213, 2009. 20(3):520–525, 2009.
35. Abrahamsson A, Albertsson-Lindblad A, Brown PN, et al: Real world 51. O’Connor OA, Moskowitz C, Portlock C, et al: Patients with
data on primary treatment for mantle cell lymphoma: a Nordic Lym- chemotherapy-refractory mantle cell lymphoma experience high response
phoma Group observational study. Blood 124(8):1288–1295, 2014. rates and identical progression-free survivals compared with patients with
36. Guru Murthy GS, Venkitachalam R, Mehta P: Effect of radiotherapy on relapsed disease following treatment with single agent bortezomib: results
the survival of patients with stage I and stage II mantle cell lymphoma: of a multicentre Phase 2 clinical trial. Br J Haematol 145(1):34–39, 2009.
analysis of the Surveillance, Epidemiology and End Results database. 52. Wang M, Oki Y, Pro B, et al: Phase II study of yttrium-90-ibritumomab
Clin Lymphoma Myeloma Leuk 14(Suppl):S90–S95, 2014. tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J
37. Robak T, Huang H, Jin J, et al: Bortezomib-based therapy for newly Clin Oncol 27(31):5213–5218, 2009.
diagnosed mantle-cell lymphoma. N Engl J Med 372(10):944–953, 53. Baiocchi RA, Alinari L, Lustberg ME, et al: Phase 2 trial of rituximab
2015. and bortezomib in patients with relapsed or refractory mantle cell and
38. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloabla- follicular lymphoma. Cancer 117(11):2442–2451, 2011.
tive radiochemotherapy followed by autologous stem cell transplantation 54. Lamm W, Kaufmann H, Raderer M, et al: Bortezomib combined with
in first remission significantly prolongs progression-free survival in rituximab and dexamethasone is an active regimen for patients with
mantle-cell lymphoma: results of a prospective randomized trial of the relapsed and chemotherapy-refractory mantle cell lymphoma. Haemato-
European MCL Network. Blood 105(7):2677–2684, 2005. logica 96(7):1008–1014, 2011.
39. Geisler CH, Kolstad A, Laurell A, et al: Long-term progression-free 55. Ansell SM, Tang H, Kurtin PJ, et al: Temsirolimus and rituximab in
survival of mantle cell lymphoma after intensive front-line immuno- patients with relapsed or refractory mantle cell lymphoma: a phase 2
chemotherapy with in vivo-purged stem cell rescue: a nonrandomized study. Lancet Oncol 12(4):361–368, 2011.
phase 2 multicenter study by the Nordic Lymphoma Group. Blood 56. Wang M, Fayad L, Wagner-Bartak N, et al: Lenalidomide in combina-
112(7):2687–2693, 2008. tion with rituximab for patients with relapsed or refractory mantle-cell
40. LaCasce AS, Vandergrift JL, Rodriguez MA, et al: Comparative outcome lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716–723, 2012.
of initial therapy for younger patients with mantle cell lymphoma: an 57. Zaja F, De Luca S, Vitolo U, et al: Salvage treatment with lenalidomide
analysis from the NCCN NHL Database. Blood 119(9):2093–2099, and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical
2012. results and effects on microenvironment and neo-angiogenic biomarkers.
41. Budde LE, Guthrie KA, Till BG, et al: Mantle cell lymphoma interna- Haematologica 97(3):416–422, 2012.
tional prognostic index but not pretransplantation induction regimen 58. Renner C, Zinzani PL, Gressin R, et al: A multicenter phase II trial (SAKK
predicts survival for patients with mantle-cell lymphoma receiving high- 36/06) of single-agent everolimus (RAD001) in patients with relapsed
dose therapy and autologous stem-cell transplantation. J Clin Oncol or refractory mantle cell lymphoma. Haematologica 97(7):1085–1091,
29(22):3023–3029, 2011. 2012.
42. Andersen NS, Pedersen LB, Laurell A, et al: Pre-emptive treatment with 59. Kahl BS, Spurgeon SE, Furman RR, et al: A phase 1 study of the
rituximab of molecular relapse after autologous stem cell transplantation PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle
in mantle cell lymphoma. J Clin Oncol 27(26):4365–4370, 2009. cell lymphoma (MCL). Blood 123(22):3398–3405, 2014.
43. Wang ML, Rule S, Martin P, et al: Targeting BTK with ibrutinib in 60. Fenske TS, Zhang MJ, Carreras J, et al: Autologous or reduced-
relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507– intensity conditioning allogeneic hematopoietic cell transplantation for
516, 2013. chemotherapy-sensitive mantle-cell lymphoma: analysis of transplanta-
44. Vose JM, Bierman PJ, Weisenburger DD, et al: Autologous hemato- tion timing and modality. J Clin Oncol 32(4):273–281, 2014.
poietic stem cell transplantation for mantle cell lymphoma. Biol Blood 61. Cook G, Smith GM, Kirkland K, et al: Outcome following Reduced-
Marrow Transplant 6(6):640–645, 2000. Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for
45. Ganti AK, Bierman PJ, Lynch JC, et al: Hematopoietic stem cell trans- relapsed and refractory mantle cell lymphoma (MCL): a study of the
plantation in mantle cell lymphoma. Ann Oncol 16(4):618–624, 2005. British Society for Blood and Marrow Transplantation. Biol Blood
46. Gopal AK, Rajendran JG, Petersdorf SH, et al: High-dose chemo- Marrow Transplant 16(10):1419–1427, 2010.
radioimmunotherapy with autologous stem cell support for relapsed 62. Maris MB, Sandmaier BM, Storer BE, et al: Allogeneic hematopoietic
mantle cell lymphoma. Blood 99(9):3158–3162, 2002. cell transplantation after fludarabine and 2 Gy total body irradiation for
47. Rummel MJ, Al-Batran SE, Kim SZ, et al: Bendamustine plus ritux- relapsed and refractory mantle cell lymphoma. Blood 104(12):3535–3542,
imab is effective and has a favorable toxicity profile in the treatment 2004.
of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 63. Caballero D, Campo E, Lopez-Guillermo A, et al: Clinical practice
23(15):3383–3389, 2005. guidelines for diagnosis, treatment, and follow-up of patients with
48. Robinson KS, Williams ME, van der Jagt RH, et al: Phase II multi- mantle cell lymphoma. Recommendations from the GEL/TAMO
center study of bendamustine plus rituximab in patients with relapsed Spanish Cooperative Group. Ann Hematol 92(9):1151–1179, 2013.
indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 64. Hoster E, Dreyling M, Klapper W, et al: A new prognostic index
26(27):4473–4479, 2008. (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood
49. Inwards DJ, Fishkin PA, Hillman DW, et al: Long-term results of 111(2):558–565, 2008.
the treatment of patients with mantle cell lymphoma with cladribine 65. Chandran R, Gardiner SK, Simon M, et al: Survival trends in mantle
(2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the cell lymphoma in the United States over 16 years 1992–2007. Leuk
North Central Cancer Treatment Group. Cancer 113(1):108–116, 2008. Lymphoma 53(8):1488–1493, 2012.